IFF Tackles Top Challenges in Baking at IBIE 2025
2.9.2025 13:00:00 CEST | Business Wire | Press Release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, health and biosciences, will showcase how it is helping the global baking industry overcome some of its toughest challenges at the International Baking Industry Exposition (IBIE) 2025 in Las Vegas. From soaring cocoa and egg prices to stricter regulations and rising demand for healthier baked goods, IFF is stepping forward with bold, science-led solutions designed to keep industrial bakers ahead of the curve.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250902465856/en/
“The industry is under pressure from every direction — supply chains, regulations and consumer expectations,” said Suzanne Pera, vice president and regional general manager for North America, IFF Food Ingredients. “Our message at IBIE is simple: Bakers don’t have to face these challenges alone. We bring unmatched expertise across the entire process, from formulation to shelf. We’re not just helping bakers adapt — we’re helping them win.”
Addressing the cost of volatility
With cocoa prices doubling and egg supplies remaining strained, IFF CURE™ — a comprehensive suite of Core and Uncommon Replacements and Extenders — offers solutions that maintain taste and texture while reducing reliance on volatile commodities. At the booth, visitors can sample 50 percent egg-reduced cupcakes and 30 percent cocoa-reduced brownies made with proprietary enzyme blends, system blends and natural flavors.
Navigating regulatory shifts
With certain food dyes now banned and the industry reevaluating what quantifies as “healthy,” bakers face increasing reformulation demands. IFF spotlights natural color alternatives, label-friendly hydrocolloids and shelf-life extension solutions that keep products compliant without sacrificing sensory appeal.
Meeting the health-conscious consumer
GLP-1 users are reshaping food and beverage demand, while shoppers broadly seek lower sugar, more protein and label-friendly bakery options. The prototypes reflect how IFF translates consumer and regulatory insights into market-ready products, featuring better-for-you concepts like high-protein tortillas and consumer-validated nutrition bars fortified with SOLAE® SUPRO® soy protein and LITESSE® ULTRA prebiotic fiber.
Breakthrough baking technologies debut
IFF will debut DANISCO® GRINDSTED® Pectin FB 420, a bake-stable pectin made from citrus peels. This naturally sourced, label-friendly alternative to starch enhances flavor release and mouthfeel, while delivering a bright, glossy texture in reduced-sugar bakery applications. Also launching is POWERFRESH® ACE 2000, a next-generation fresh-keeping enzyme that improves bread softness, resilience and cohesiveness for up to 34 days.
“We are not just displaying ingredients,” said Linda Dunning, applications director, North America, IFF Food Ingredients. “We are showing how real-world solutions can raise the game for bakers — ideas that work in the lab, are scalable in production and stand out on the shelf.”
Attendees will experience go-to-market applications, designed to inspire product innovations while solving some of the baking industry’s toughest challenges. IFF will be at IBIE 2025 from Sept. 14-17 at the Las Vegas Convention Center, booth 3855.
To learn more about IFF at IBIE and its bold, future-forward baking solutions, visit the IFF IBIE 2025 page here.
Welcome to IFF
At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products — advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook.
©2025 International Flavors & Fragrances Inc. (IFF). IFF, the IFF Logo, and all trademarks and service marks denoted with ™, SM or ® are owned by IFF or affiliates of IFF unless otherwise noted. All Rights Reserved.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250902465856/en/
Contacts
Jasmine Chia
Global Communications Director, Food Ingredients
+65 9827 3808
Jasmine.Chia@iff.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press Release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom